Krüger K
Rheumazentrum München, Germany.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2002 Sep;45(9):699-706. doi: 10.1007/s00103-002-0451-y.
Multiple studies in osteoarthritis (OA), rheumatoid arthritis (RA), and several acute pain models indicate that the cyclooxygenase-2-specific inhibitors celecoxib and rofecoxib are equally effective as the conventional nonsteroidal antirheumatic drugs diclofenac, ibuprofen, and naproxen. Both drugs are approved for the treatment of OA and RA in a daily dosage of 2×100 mg, 1×200 mg, and 2×200 mg (celecoxib) or 1×12.5 mg and 1×25 mg (rofecoxib). In addition, rofecoxib has also been approved by the FDA for the treatment of postsurgical pain in a dosage of 50 mg. Normally celecoxib is used in a dosage of 1×200 mg for OA and 2×200 mg for RA, whereas both 12.5 and 25 mg rofecoxib are used for the treatment of OA and 25 mg for the treatment of RA. Coxibs might also be used for the treatment of seronegative spondarthritides, as is indicated by a successful study using celecoxib for the treatment of ankylosing spondylitis.
多项针对骨关节炎（OA）、类风湿关节炎（RA）以及多种急性疼痛模型的研究表明，环氧化酶-2特异性抑制剂塞来昔布和罗非昔布与传统非甾体类抗风湿药物双氯芬酸、布洛芬和萘普生的疗效相当。这两种药物均已获批用于治疗OA和RA，塞来昔布的日剂量为2×100mg、1×200mg和2×200mg，罗非昔布的日剂量为1×12.5mg和1×25mg。此外，罗非昔布还被美国食品药品监督管理局（FDA）批准用于治疗术后疼痛，剂量为50mg。通常情况下，塞来昔布治疗OA的剂量为1×200mg，治疗RA的剂量为2×200mg；而罗非昔布治疗OA的剂量为12.5mg和25mg，治疗RA的剂量为25mg。一项使用塞来昔布治疗强直性脊柱炎的成功研究表明，昔布类药物也可能用于治疗血清阴性脊柱关节炎。
